Amid a Republican push to repeal and replace Obamacare, Pfizer CEO Ian Read took his drug pricing message to the Washington press corps.
President Donald Trump, not content with making drugs more affordable in the U.S., says he's aiming to push prices lower than anywhere else in the world.
The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…
Valeant is shelling out a hefty sum on its chief exec’s pay package for a pharma company—let alone a pharma company that’s struggling under a mountain of debt.
Changes are afoot at foundering Teva—and they include layoffs and a hiring freeze.
Sanofi is in talks to buy Flexion Therapeutics, a biotech with its lead product awaiting FDA approval, for more than $1 billion, according to a source close to…
When PTC agreed to buy Marathon's Emflaza last week, it inherited congressional scrutiny on the drug's price, originally set at a much-lambasted $89,…
After taking a beating over a proposed Zika vaccine license from the U.S. Army, Sanofi is hitting back.
New England Compounding Center's contaminated drugs caused a fungal meningitis outbreak that killed more than 60 people.
With stellar vaccine sales for GlaxoSmithKline and Bexsero, GSK is building a $175 million plant in Germany to expand production of the meningococcal B shot.
Pharma patent challenger Kyle Bass has lost his second round at the U.S. Patent and Trademark Office in as many weeks, and this time, the win is Biogen’s.